Global Hospital-acquired Pneumonia Drugs Market Details Analysis

Global Hospital-acquired Pneumonia Drugs Market
to Stand at US$3.8 bn by 2020 fueled by Imminent
Launches
The incidence of healthcare associated pneumonia or global hospital-acquired pneumonia drugs
market is showing a progressive increase; however, the multidrug resistance shown by
microorganisms that cause nosocomial infections has created a large market for drugs that treat
hospital-acquired pneumonia. According to the report, six major phase III drugs will collectively
generate revenue to the tune of US$3.8 bn by 2020.
The appreciable demand for hospital-acquired pneumonia falls into perspective when one
considers the fact that pneumonia accounts for over 22% of all hospital-acquired infections.
Often, conventional antibiotics are unable to treat multidrug resistant organisms, creating a
sizeable unmet demand for effective drugs for not just hospital-acquired pneumonia but also for
other kinds of hospital acquired infections.
However, the astounding amounts of money spent on combating hospital-acquired drugs has
forced governments to impose strict policies to address the root causes of such infections. As
many of these programs meet success, the incidence rate of hospital-acquired infections will
likely see a dip. This will, in turn, lead to a decline in the demand for hospital-acquired
pneumonia drugs. The report terms this trend as an impending restraint for the growth of the
global hospital-acquired pneumonia drugs market.
Hospital-acquired pneumonia, which is also sometimes referred to as ventilator-associated
pneumonia, is typically seen among patients who are immunocompromised patients, on enteral
feeding, or have undergone surgery. Infants, too, face a risk of acquiring hospital-acquired
pneumonia. Among the newborn, respiratory syncytial virus (RSV) is identified as being the
major cause of nosocomial pneumonia.
The global hospital-acquired pneumonia drugs market currently features one vaccine and five
investigational drugs in clinical trials phase III. It is estimated that many of these drugs will hit
the market in 2017. The following drugs are currently in phase III of clinical trials, as per the
report: Cubist Pharmaceuticals’ Ceftolozane/tazobactam and tedizolid phosphate, AstraZeneca
PLC’s Ceftazidime/avibactam, Bayer Healthcare’s Amikacin inhale, Achaogen, Inc.’s
Plazomicin, and GlaxoSmithKline’s Synflorix. Of these, tedizolid phosphate is emerging as the
most preferred drug for treating nosocomial pneumonia.

TMR’s analysis reveals that many of the candidates that are expected to be launched over the
coming years are biological drugs. With this, it can be gauged that a paradigm shift is taking
place from traditional antibiotic therapy to more sophisticated biological drug therapy. With four
drug candidates for hospital-acquired pneumonia, the pipeline of Aridis Pharmaceuticals is seen
to be the strongest, and each of these drugs is a monoclonal antibody therapy.
In addition to these drugs, the market also features ten drugs that are in the early clinical trial
stages. The market is characterized by numerous research and development activities.Companies
that currently hold a strong position in the global hospital acquired pneumonia drugs market are:
Achaogen, Inc., AstraZeneca PLC, Aridis Pharmaceutical, Valneva SE, Bayer Healthcare,
Basilea Pharmaceutica Ltd., Cubist Pharmaceutical, Meiji Seika Pharma Co., Ltd.,
GlaxoSmithKline, and Merck & Co.
Global Hospital Acquired Pneumonia Drug Pipeline, Late Stage Candidates (Phase III)
Tedizolid phosphate
Ceftolozane/tazobactam
Ceftazidime/avibactam
Amikacin inhale
Plazomicin
Synflorix
Global Hospital Acquired Pneumonia Drug Pipeline, Early Stage Candidates (Phase II,
Phase I and Preclinical Trials)
AR-101 or KBPA101
GSK 2189242A
BAL30072
MEDI4893
AR 301 or KBSA301
ME1100
V114
AR-104 or KBPA104
AR-201 or KBRV201
AR-401 or KBAB401
Browse Full Press Release on Hospital-acquired Pneumonia Drugs Market:
Press Release

About Us
Transparency Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight for thousands of decision
makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that
it always reflects the latest trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous primary and secondary research
techniques to develop distinctive data sets and research material for business reports.
Contact Us
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com